Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19.
J Nanobiotechnology
; 19(1): 173, 2021 Jun 10.
Article
in English
| MEDLINE | ID: covidwho-1266489
ABSTRACT
BACKGROUND:
The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit the process of CSS by controlling excessive inflammation is considered one of the most promising ways for COVID-19 treatment.RESULTS:
Here, we developed a biomimetic nanocarrier based drug delivery system against COVID-19 via anti-inflammation and antiviral treatment simultaneously. Firstly, lopinavir (LPV) as model antiviral drug was loaded in the polymeric nanoparticles (PLGA-LPV NPs). Afterwards, macrophage membranes were coated on the PLGA-LPV NPs to constitute drugs loaded macrophage biomimetic nanocarriers (PLGA-LPV@M). In the study, PLGA-LPV@M could neutralize multiple proinflammatory cytokines and effectively suppress the activation of macrophages and neutrophils. Furthermore, the formation of NETs induced by COVID-19 patients serum could be reduced by PLGA-LPV@M as well. In a mouse model of coronavirus infection, PLGA-LPV@M exhibited significant targeted ability to inflammation sites, and superior therapeutic efficacy in inflammation alleviation and tissues viral loads reduction.CONCLUSION:
Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Drug Carriers
/
Biomimetics
/
Nanoparticles
/
Cytokine Release Syndrome
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Inflammation
/
Anti-Inflammatory Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Nanobiotechnology
Year:
2021
Document Type:
Article
Affiliation country:
S12951-021-00926-0
Similar
MEDLINE
...
LILACS
LIS